Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine

Nóbrega, Giulliana; Cavalcanti, Milena Paiva; Leite, Verônica; Vilar, Lúcio; Brandão, Simone Cristina Soares

doi:10.1007/s12020-022-03021-y

Cited by 6 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose of radioactive iodine should be increased when the biochemical level is high. The level of Ps-Tg can be used as a guiding factor for increasing the dose of radioactive iodine in patients with PTC [30]. Studies should be conducted to explore the optimal dose of radioactive iodine for 131 I therapy.…”

Section: Discussionmentioning

confidence: 99%

Effect of Hashimoto’s Thyroiditis on Efficacy of <sup>131</sup>I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma

Zhou¹,

Cheng²

2023

JBM

View full text Add to dashboard Cite

Objective: The purpose of this study was to investigate the effect of Hashimoto's thyroiditis on efficacy of 131 I ablation in intermediate-and high-risk of thyroid papillary carcinoma patients. The findings will help to develop a personalized treatment plan for patients with thyroid papillary carcinoma complicated with Hashimoto's thyroiditis. Material and Methods: From January 2016 to December 2020, patients who were diagnosed with intermediate-and high-risk PTC with lymph node metastasis were analyzed retrospectively, excluding patients with incomplete clinical data, distant metastasis, positive TGAb, TSH < 30 mIU/L. The baseline data of sex, age, and biochemical information were collected before admission. All patients included had radioactive iodine (RAI) with 3.70 GBq. The treatment response of patients was evaluated 6 -8 months after discharge. By means of univariate and multivariate analysis, including excellent response (ER) and non-excellent response (NER) groups of clinical data, we assessed the impact of 131 I on patients outcome. Results: A total of 525 patients (166 males and 359 females) were included in the study, including 368 patients in ER group (70.1%) and 157 patients in NER group (29.9%). Eleven factors including combining Hashimoto's thyroiditis, pre-ablative Tg levels, sex, tumor diameter, extraglandular invasion, multifocal, bilateral lesions, central lymph node metastasis, lateral lymph node metastasis, lymph node metastasis rate, thyroglobulin were statistically different between ER group and NER group with significance at P < 0.05. Further multivariate analysis showed that Hashimoto's thyroiditis, Ps-Tg levels and lateral lymph node metastasis could be used as independent factors. And patients with HT had significantly superior outcomes compared with patients without HT. Conclusion: Hashimoto's thyroiditis, Ps-Tg level and lateral lymph node metastasis are potential predictors for short-term efficacy of 131 I treatment in intermediate-and high-risk thyroid papillary carcinoma. Ha-How to cite this paper: Zhou, L. and Cheng, G. (2023) Effect of Hashimoto's Thyroiditis on Efficacy of 131 I Ablation Therapy in Intermediate-and High-Risk of Thyroid

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Hashimoto’s Thyroiditis on Efficacy of <sup>131</sup>I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma

Zhou¹,

Cheng²

2023

JBM

View full text Add to dashboard Cite

show abstract

“…Two randomised trials (HiLo and ESTIMABL1) reported similar post-ablation success at 6-9 months and recurrence rates in patients with well-differentiated thyroid cancer when comparing 1.1 GBq and 3.7 GBq (9)(10)(11). Further studies are studying prognostic markers to predict ablation success (12). Ablation success has been hypothesised to be dependent on the absorbed dose delivered to any residual thyroid tissue rather than the RAI administered activity (13-16) with several studies showing a large range of absorbed doses for empiric activities (13-21).…”

Section: Introductionmentioning

confidence: 99%

Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

et al. 2023

View full text Add to dashboard Cite

IntroductionThe optimal strategy for differentiated thyroid cancer (DTC) patients treated with radioiodine (RAI) following thyroidectomy remains controversial. Multi-centre clinical studies are essential to identify strategies to improve patient outcomes while minimising treatment-induced toxicity.MethodsThe INSPIRE clinical trial (ClinicalTrials.gov Identifier: NCT04391244) aims to investigate patient-specific dosimetry for DTC patients and to determine the range of absorbed doses delivered to target and non-target tissues and their relationship with treatment outcome and toxicity.ResultsWe report here initial results of the first 30 patients enrolled onto the INSPIRE trial. A large range of absorbed doses are observed for both thyroid remnants and salivary glands, with median values of 4.8 Gy (Range 0.2 – 242 Gy) and 0.3 Gy (Range 0.1 to 1.7 Gy), respectively.DiscussionThe preliminary study results are encouraging and could help to improve our understanding of absorbed doses to thyroid remnants and normal organs following RAI therapy. Such knowledge could potentially enable patient-specific treatment planning with improved clinical outcomes and quality-of-life of patients.

show abstract

Retrospective case–control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer

Watanabe,

Igarashi,

Uchiyama

et al. 2024

Jpn J Radiol

View full text Add to dashboard Cite

Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine

Cited by 6 publications

References 22 publications

Effect of Hashimoto’s Thyroiditis on Efficacy of <sup>131</sup>I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma

Effect of Hashimoto’s Thyroiditis on Efficacy of <sup>131</sup>I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma

Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

Retrospective case–control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer

Contact Info

Product

Resources

About

Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine

Cited by 6 publications

References 22 publications

Effect of Hashimoto’s Thyroiditis on Efficacy of &lt;sup&gt;131&lt;/sup&gt;I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma

Effect of Hashimoto’s Thyroiditis on Efficacy of &lt;sup&gt;131&lt;/sup&gt;I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma

Initial results of the INSPIRE clinical trial—investigating radiation dosimetry for differentiated thyroid cancer patients

Retrospective case–control study examining the relationship between recurrence-free survival and changes in pre- and post-radioiodine therapy serum thyroglobulin levels in patients with differentiated thyroid cancer

Contact Info

Product

Resources

About

Effect of Hashimoto’s Thyroiditis on Efficacy of <sup>131</sup>I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma

Effect of Hashimoto’s Thyroiditis on Efficacy of <sup>131</sup>I Ablation Therapy in Intermediate- and High-Risk of Thyroid Papillary Carcinoma